| Excerpt | Relevance | Reference |
|---|
| "Twenty patients with metastatic breast cancer were treated every 3 weeks with TFP 5 mg by mouth every 6 hours on days 0-5 and doxorubicin 60 mg/m2/96 hr on days 1-4 by continuous intravenous infusion." | 6.67 | Phase II trial of doxorubicin and trifluoperazine in metastatic breast cancer. ( Bauer, L; Budd, GT; Bukowski, RM; Ganapathi, R; Lichtin, A; Van Kirk, P, 1993) |
| "Twenty patients with metastatic breast cancer were treated every 3 weeks with TFP 5 mg by mouth every 6 hours on days 0-5 and doxorubicin 60 mg/m2/96 hr on days 1-4 by continuous intravenous infusion." | 2.67 | Phase II trial of doxorubicin and trifluoperazine in metastatic breast cancer. ( Bauer, L; Budd, GT; Bukowski, RM; Ganapathi, R; Lichtin, A; Van Kirk, P, 1993) |